Notice for sabizabulin (Adjutor Healthcare Pty Ltd)
Active ingredients
sabizabulin
Sponsor
Date of review outcome
Lapse date
Type
Provisional determination
Indication
For treatment of SARS-CoV-2 infection in hospitalised patients with moderate to severe COVID-19 infection who are at high risk for Acute Respiratory Distress Syndrome (ARDS)
Therapeutic area
Infectious diseases